ArticleCellular and molecular life sciences : CMLS2026
CircGRHL2 suppresses EMT and enhances sunitinib sensitivity in ccRCC via the miR-330-5p/FBXO21 axis.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Clear cell renal cell carcinoma (ccRCC) is one of the most common cancers in the urinary system. Studies have shown that circRNAs have potential effects in a variety of human tumors. Studying the important signaling pathways and therapeutic targets of circRNAs is essential to increase understanding of ccRCC. In this present study, we clarified that hsa_circGRHL2 was dramatically decreased in ccRCC tissues and cells, which was closely related to the clinicopathological features of ccRCC patients. Functionally, circGRHL2 significantly inhibited the proliferation, migration, and invasion of ccRCC cells in vitro. Mechanistically, circGRHL2 sponges miR-330-5p, could regulate miR-330-5p to affect proliferation, migration, invasion of ccRCC cells and have effect on epithelial-mesenchymal transition (EMT). Moreover, FBXO21, could be a direct target of miR-330-5p, which further reducing P85 phosphorylation, inhibiting PI3K/AKT pathway activation, and weakening the EMT. In addition, circGRHL2 overexpression enhances the sensitivity of 769-P cells to sunitinib and enhances the ability of sunitinib treatment effects in vivo. In summary, we proposed a novel signaling network, in which circGRHL2 inhibited the progression of ccRCC via the miR-330-5p/FBXO21 axis and decreased PI3K/AKT activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.